Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

NCT01729923 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01729923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01729923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2013
Completion date
September 6, 2016
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent colon carcinoma, recurrent rectal carcinoma, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer